Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6010 plus osimertinib vs osimertinib as neoadjuvant therapy in resectable stage II–IIIb EGFR-mutant NSCLC
CTR20254512Phase 2Active
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Nov 2025
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of CPO301, osimertinib in Non-small cell lung cancer (NS-NSCLC), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Started Nov 2025; status: active.
02
Drugs
CPO301osimertinib
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on CTR20254512.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254512.